中国同辐附属原子高科参与“儿童神经母细胞瘤多模态核医学分子影像体系的建立”项目荣获北京医学科技奖一等奖

Core Viewpoint - China Tongru (01763) announced that the project "Establishment of a Multimodal Nuclear Medicine Molecular Imaging System for Pediatric Neuroblastoma," involving Yuanzi Gaoke Co., Ltd., won the first prize at this year's Beijing Medical Science and Technology Awards [1] Group 1: Project Overview - Neuroblastoma is the most common extracranial solid tumor in children, accounting for approximately 8%-10% of pediatric malignant tumors and leading to about 10%-15% of childhood cancer-related deaths [1] - More than half of the patients are classified as high-risk at initial diagnosis, with a poor prognosis and a five-year survival rate of less than 50% [1] - The project focuses on addressing the challenges posed by neuroblastoma, which is referred to as the "king of childhood cancers," and aims to contribute to public health in China [1] Group 2: Technological Achievements - The project has established a complete independent innovation chain from key equipment and core drugs to clinical applications, creating a "multimodal, low-dose, short-duration" precision diagnosis and treatment system for neuroblastoma [1] - Yuanzi Gaoke has developed the positron-emitting radiopharmaceutical sodium fluoride [18F] injection, completed Phase III clinical trials, and successfully registered it, filling a gap in domestic bone imaging radiopharmaceuticals [2] - The company has also led the development of the iodine [123I] sodium solution radiopharmaceutical group standard and collaborated with the Friendship Hospital to provide a basis for standardized production of domestic radiopharmaceuticals [2] Group 3: Strategic Collaboration - Yuanzi Gaoke and the nuclear medicine department of the Friendship Hospital have established a long-term strategic partnership based on the concept of "industry-university-research-medical collaboration" [2] - The collaboration has resulted in significant advancements in radiopharmaceutical supply, research platform construction, and clinical trial promotion [2] - Moving forward, Yuanzi Gaoke will continue to focus on the field of nuclear medicine, increase investment in radiopharmaceutical research and technological innovation, and deepen cooperation with clinical institutions to enhance precision medical development [2]